Although our results suggested that in the mouse model, PSMB10 downregulation sensitized AML cells to AraC/ADM treatment and enhanced the in vivo clearance of drug-resistant LSCs by increased intracellular drug concentrations and drug-induced cellular senescence, as well as enhanced cytotoxic T lymphocyte-mediated killing in a ubiquitinated degradation manner, while normal hematopoietic cells remained unaffected. Here, PSMB10 is linked to acute myeloid leukemia.